Lymphoma News

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release.

Arya Amini, MD, still remembers sitting on the steps outside of his dean’s office at University of California, Irvine, more than a decade ago, prepared to race inside in case he did not get matched with a radiation oncology residency.

Liquid biopsy could provide enhanced information about chimeric antigen receptor T-cell therapy compared with normally used DNA, RNA and protein assays, according to findings published in Journal for ImmunoTherapy of Cancer.

Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.

The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

The Lymphoma Research Foundation formed a multidisciplinary consortium dedicated to advancing and harmonizing treatment for adolescents and young adults with lymphoma.

Steven A. Rosenberg, MD, PhD, FAACR, will be awarded the 2024 American Association for Cancer Research Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting in San Diego.

More evidence has emerged that T-cell lymphoma following chimeric antigen receptor T-cell therapy is both rare and not necessarily caused by the treatment.

Extended family members of men with severe subfertility or infertility may have an increased risk for several different cancer types, study results published in Human Reproduction showed.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.